Cat. #156502
STAT2-Defective Mutant Daudi (RST2) cell line
Cat. #: 156502
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Availability: 10-12 weeks
Organism: Human
Tissue: Blood
Disease: Cancer
Model: Transgenic
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Lawrence Pfeffer
Institute: The University of Tennessee Health Science Center
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: STAT2-Defective Mutant Daudi (RST2) cell line
- Cancer: Blood cancer
- Cancers detailed: Burkitt lymphoma
- Research fields: Cancer
- Tool sub type: Continuous
- Parental cell: Human Daudi Burkitt Lymphoma cell line
- Organism: Human
- Tissue: Blood
- Disease: Cancer
- Model: Transgenic
- Description: This cell line can be used to study drug resistance developed after treatment with interferon. Interferon therapy has been proved as a successful treatment for various types of cancer, however it develops resistance in patients. This cell line was not affected by the antiviral, antiproliferative, and gene-inducing actions of IFN.
- Production details: Isolated from IFN-sensitive Daudi cell line by growth in the continuous presence of IFN
- Recommended controls: Human Daudi Burkitt Lymphoma parental line
Handling
- Format: Frozen
- Growth medium: RPMI1640 and 10% defined calf serum; Subculture 1:4 twice a week, maintain 1 and 10X10^5 cells/mL
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
References
- Schmeisser et al. 2013. Autophagy. 9(5):683-96. PMID: 23419269.
- Du et al. 2009. J Biol Chem. 284(41):27808-15. PMID: 19687011.
